Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Incyte gets global rights to Hengrui's anticancer immunotherapy

Executive Summary

Jiangsu Hengrui Medicine Co. Ltd. (Hengrui) granted Incyte Corp. exclusive global development and commercialization rights to the preclinical anti-PD-1 mAb SHR1210. Incyte’s rights do not include Mainland China, Hong Kong, Macau, and Taiwan.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies